Investigational Site Number :3920016

Nagoya, Aichi-ken 460-0001

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer

Studies at this site

• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early